X4 Pharmaceuticals (XFOR) Cash from Financing Activities (2017 - 2025)

X4 Pharmaceuticals has reported Cash from Financing Activities for 9 years, with the latest figure at $146.1 million in Q4 2025.

• For the quarter ending Q4 2025, Cash from Financing Activities rose 108116.3% year-over-year to $146.1 million; the trailing twelve-month figure through Dec 2025 stood at $238.6 million (up 1075.85% YoY), and the FY2025 full-year result was $238.6 million, up 1075.85% from the prior year.
• Cash from Financing Activities for Q4 2025 stood at $146.1 million, up from $86.9 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $146.1 million in Q4 2025, with the low at -$4.4 million in Q3 2021.
• Historically, Cash from Financing Activities has averaged $31.7 million across 5 years, with a median of $20.2 million in 2024.
• Annual changes were most pronounced in 2021 — Cash from Financing Activities plunged 1521.54% — and 2025, when it jumped 108116.3%.
• X4 Pharmaceuticals' Cash from Financing Activities stood at $24.6 million in 2021, then soared by 146.82% to $60.6 million in 2022, then plunged by 99.84% to $97000.0 in 2023, then surged by 39.18% to $135000.0 in 2024, then jumped by 108116.3% to $146.1 million in 2025.
• The last three Cash from Financing Activities figures came in at $146.1 million (Q4 2025), $86.9 million (Q3 2025), and $5.6 million (Q2 2025), per Business Quant data.